Article
Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
CPT: pharmacometrics & systems pharmacology - 1 Sept 2021
De Zwart Loeckie, Snoeys Jan, Jacobs Frank, Li Lilian Y, Poggesi Italo, Verboven Peter, Goris Ivo, Scheers Ellen, Wynant Inneke, Monshouwer Mario, Mamidi Rao N V S
Abstract excerpt
Erdafitinib is a potent oral pan-fibroblast growth factor receptor inhibitor being developed as oncology drug for patients with alterations in the fibroblast growth factor receptor pathway. Erdafitinib binds preferentially to α1-acid glycoprotein (AGP) and is primarily metabolized by cytochrome P450 (CYP) 2C9 and 3A4. This article describes a physiologically based pharmacokinetic (PBPK) model for erdafitinib to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.